Table 3 Sites of clinically suspected infections and use of antibiotics at baseline (safety population)
AZD9773 cohort 1 (50 U/kg) (n= 8) | AZD9773 cohort 2 (250 U/kg) (n= 9) | AZD9773 cohort 3 (250/50 U/kg) (n= 12) | AZD9773 cohort 4 (500/100 U/kg) (n= 10) | AZD9773 cohort 5 (750/250 U/kg) (n= 8) | Placebo (n= 23) | Total (n= 70) | |
|---|---|---|---|---|---|---|---|
Infection site, n (%) | |||||||
Abdomen | 2 (25.0) | 3 (33.3) | 2 (16.7) | 1 (10.0) | 5 (62.5) | 3 (13.0) | 16 (22.9) |
Catheter/device | 1 (12.5) | 0 | 0 | 0 | 0 | 0 | 1 (1.4) |
Lung | 3 (37.5) | 4 (44.4) | 6 (50.0) | 6 (60.0) | 2 (25.0) | 12 (52.2) | 33 (47.1) |
Skin and soft tissue | 1 (12.5) | 1 (11.1) | 1 (8.3) | 1 (10.0) | 0 | 4 (17.4) | 8 (11.4) |
Unknown | 1 (12.5) | 1 (11.1) | 2 (16.7) | 2 (20.0) | 0 | 1 (4.3) | 7 (10.0) |
Urinary tract | 0 | 0 | 3 (25.0) | 0 | 1 (12.5) | 3 (13.0) | 7 (10.0) |
Time from qualifying organ failure to first antibiotic use, hours* | |||||||
( n = 7) | ( n = 6) | ( n = 9) | ( n = 7) | ( n = 8) | ( n = 19) | ( n = 56) | |
Median (range) | -4.4 (-39.0 to 20.6) | -10.1 (-85.7 to 0.7) | -0.8 (-41.3 to 16.4) | -3.9 (-108.2 to 1.2) | -6.3 (-85.1 to 6.5) | -4.9 (-366.5 to 12.8) | -4.2 (-366.5 to 20.6) |